Vera Therapeutics Inc Cash Flow Conversion Efficiency
Vera Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Vera Therapeutics Inc (VERA) has a cash flow conversion efficiency ratio of -0.213x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-106.50 Million) by net assets ($499.70 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Vera Therapeutics Inc (2019–2025)
Cash flow conversion efficiency of Vera Therapeutics Inc from 2019 to 2025. This chart illustrates how Vera Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Vera Therapeutics Inc stock price for real-time trading data and today's change.
Vera Therapeutics Inc Cash Flow Conversion Ratio Explained
Vera Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Vera Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vera Therapeutics Inc ranked by their cash flow conversion efficiency. Also see how much is Vera Therapeutics Inc worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fabege AB
ST:FABG
|
0.023x |
|
Bonesupport Holding AB
ST:BONEX
|
0.085x |
|
Biohaven Ltd.
NYSE:BHVN
|
-1.158x |
|
Zhejiang Weixing Industrial Development Co Ltd
SHE:002003
|
0.063x |
|
Nuscale Power Corp
NYSE:SMR
|
-0.029x |
|
89bio Inc
NASDAQ:ETNB
|
-0.192x |
|
WaFd, Inc.
NASDAQ:WAFD
|
0.023x |
|
Korea Gas Corporation
KO:036460
|
-0.081x |
Annual Cash Flow Conversion Efficiency for Vera Therapeutics Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Vera Therapeutics Inc from 2019 to 2025. Review financial flexibility index of Vera Therapeutics Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $604.52 Million | $-241.10 Million | -0.399x | -70.92% |
| 2024-12-31 | $577.15 Million | $-134.68 Million | -0.233x | +74.26% |
| 2023-12-31 | $101.69 Million | $-92.18 Million | -0.907x | -3.14% |
| 2022-12-31 | $76.91 Million | $-67.60 Million | -0.879x | -158.00% |
| 2021-12-31 | $69.59 Million | $-23.71 Million | -0.341x | -187.44% |
| 2020-12-31 | $-89.35 Million | $-34.81 Million | 0.390x | +38.39% |
| 2019-12-31 | $-36.55 Million | $-10.29 Million | 0.282x | -- |
About Vera Therapeutics Inc
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous in… Read more